// November 27, 2023
Q&A: Building a More Resilient Medicines Supply Chain
In this conversation, US Pharmacopeia (USP) Director of Regulatory and Public Policy Developm
In this conversation, US Pharmacopeia (USP) Director of Regulatory and Public Policy Developm
The development of generic versions of innovator medicines is a global public health need.
In the U.S. and around the world, quality standards developed by the U.S.
Quality should be built into the entire drug product lifecycle – including the manufacturing and